<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945657</url>
  </required_header>
  <id_info>
    <org_study_id>MEDI-MM36-206</org_study_id>
    <nct_id>NCT02945657</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis</brief_title>
  <official_title>Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to &lt; 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medimetriks Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medimetriks Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetic parameters and safety of topical
      MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label study to assess the degree of systemic exposure and safety
      of MM36 1% ointment following 4 weeks of twice daily dosing under maximal-use conditions in
      pediatric subjects with atopic dermatitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">June 8, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual plasma concentrations of MM36 and its metabolites</measure>
    <time_frame>Day 1 and 15</time_frame>
    <description>Determination of plasma concentrations of the parent compound MM36 and its metabolites after the first topical application of MM36 and after two weeks of twice daily application (steady state)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of application site AEs, of all AEs and their relationship to study drug; incidence of clinically meaningful change from baseline in safety lab parameters, ECG, vital signs; proportion of subjects who discontinue due to AE</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>AE incidence, severity and relationship to study drug</description>
  </secondary_outcome>
  <other_outcome>
    <measure>IGA</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Investigator Global Assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>BSA%</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Body Surface Area involvement</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>MM36 1% ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM36 topical ointment, 1%, applied twice daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM36 topical ointment, 1%</intervention_name>
    <description>Twice daily application for 28 consecutive days</description>
    <arm_group_label>MM36 1% ointment</arm_group_label>
    <other_name>OPA-15406</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 2 to &lt;18 years of age

          -  Diagnosis of atopic dermatitis (AD)

          -  AD affecting ≥ 35% BSA if 2 to &lt; 12 years of age or ≥ 25% if subject is ≥ 12 years of
             age (excluding scalp and venous access areas)

        Exclusion Criteria:

          -  Active or acute viral skin infection

          -  History of recurrent bacterial infection

          -  Malignancy

          -  Clinically significant history or physical findings that may pose a health risk to
             subject or may have an impact on study assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noah Rosenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medimetriks Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medimetriks Investigational Site</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Honduras</country>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

